{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"91","value":"50"},{"groupId":"OG001","lowerLimit":"66.6","upperLimit":"99.2","value":"94.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"1-yr PFS (GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"49.4","upperLimit":"95.7","value":"83.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"1-yr PFS (non-GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"96.9","value":"80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"1-yr PFS (Inconclusive/Not done)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"91","value":"50"},{"groupId":"OG001","lowerLimit":"60.2","upperLimit":"96.9","value":"88.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"2-yr PFS (GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"41.6","upperLimit":"91.4","value":"75.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"2-yr PFS (non-GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"96.9","value":"80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"2-yr PFS (Inconclusive/not done)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"91","value":"50"},{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"1-yr OS (GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"49.4","upperLimit":"95.7","value":"83.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"1-yr OS (non-GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"96.9","value":"80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"1-yr OS (Inconclusive/not done)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"91","value":"50"},{"groupId":"OG001","lowerLimit":"58.6","upperLimit":"96.7","value":"87.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"2-yr OS (GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"49.4","upperLimit":"95.7","value":"86.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"2-yr OS (non-GCB DLBCL)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"100","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"20.4","upperLimit":"96.9","value":"80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"2-yr OS (Inconclusive/not done)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Survival rates (PFS and OS at 1 year and 2 years) are reported by gene expression profiling (GEP) (germinal center B-cell \\[GCB\\], activated B-cell \\[ABC\\], unclassifiable) and immunohistochemistry \\[IHC\\] (GCB, non-GCB).","dispersionType":"95% Confidence Interval","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.","id":"OG000","title":"Dose-finding Cohort"},{"description":"Each participant in the dose expansion cohort may receive treatment for a maximum of 6 cycles (21-day cycle length) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). MTD of ibrutinib is 560 mg PO.","id":"OG001","title":"Dose Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"Survival rate at a specific time point is reported by Lymphoma cell-of-origin (COO) type.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Survival by Lymphoma Cell-of-origin (COO) Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}